Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | POLA1 | P09884 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9913181 | 0.95 | TSHR (0.52) | TSHRLMNAALDH1A1RECQLEPHX2 | |
| SCHEMBL30775458 | 0.91 | TSHR (0.52) | TSHRLMNAALDH1A1RECQLEPHX2 | |
| SCHEMBL6373627 | 0.87 | TSHR (0.56) | TSHRLMNAALDH1A1RECQLEPHX2 | |
| SCHEMBL17263259 | 0.87 | TSHR (0.44) | TSHRLMNAALDH1A1RECQLEPHX2 | |
| SCHEMBL12405770 | 0.84 | TSHR (0.43) | TSHRLMNAALDH1A1KMT2A | |
| SCHEMBL19700255 | 0.84 | TSHR (0.43) | TSHRLMNAALDH1A1KMT2A | |
| SCHEMBL15162225 | 0.83 | — | — | |
| SCHEMBL15161803 | 0.83 | — | — | |
| SCHEMBL13042886 | 0.82 | LMNA (0.41) | TSHRLMNAALDH1A1KMT2A | |
| SCHEMBL19689220 | 0.82 | KDM4E (0.47) | LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355721-A1 | SILOXANE-CONTAINING PHOSPHOLIPIDS, COMPOSITIONS AND USES THEREOF | FRAMPTON MARK B (CA) | 2017-12-14 | — | — | US | disclosed |
| US-20170355721-A1 | SILOXANE-CONTAINING PHOSPHOLIPIDS, COMPOSITIONS AND USES THEREOF | FRAMPTON MARK B (CA) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355721-A1 | SILOXANE-CONTAINING PHOSPHOLIPIDS, COMPOSITIONS AND USES THEREOF | PHOSPHO1, SGMS1, SGMS2 | TSHR 4753/4885LMNA 472/4885ALDH1A1 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.